Strong growth, messy risk
- Q1 2026 revenue rose 26% year over year to $199.4 million, helped by higher service volume.
- Management raised 2026 revenue guidance to $875 million to $885 million and adjusted EBITDA margin guidance to 12% to 13%.
- The next-generation AI algorithm could cut clinical technician review time by as much as half over time.
- The bear case is still about reimbursement, FDA cleanup, and the DOJ Civil Investigative Demand tied to Zio AT.
- Finn's low valuation score means the stock still needs clean execution to justify its price.
Growth is winning, but not alone
iRhythm had a strong start to 2026. Q1 revenue grew 26% year over year to $199.4 million, and management raised full-year revenue guidance to $875 million to $885 million. It also lifted adjusted EBITDA margin guidance to 12% to 13%, which shows the model is starting to scale.
The main upside case is simple. More doctors are ordering Zio services, and the company may become more efficient as software does more of the review work. Management said its next-generation AI algorithm could reduce clinical technician review time by as much as half over time. If the FDA clears it and the rollout works, gross margin could move higher.
The hard part is that the business still sits inside a tight legal and regulatory box. The DOJ Civil Investigative Demand into Zio AT reimbursement is unresolved. The company is also still working through FDA warning-letter cleanup and Medicare coverage questions. No new DOJ information request since December 2025 is better than bad news, but it is not a clean ending.
That balance fits Finn's score. Growth looks good, but valuation and risk keep the overall view in the middle. The stock needs more than fast sales growth. It needs clean reimbursement, FDA progress, and proof that profits can keep improving.
A patch, a report, and a payer
iRhythm makes money when a licensed health care provider orders a Zio service for a patient. The patient wears a small wireless patch that records heart rhythm data. iRhythm then processes the data through its cloud system and delivers a report to the clinician.
Most revenue comes from third-party payers, including commercial insurers and Medicare. In Q1 2026, contracted third-party payors were 53% of revenue and CMS was 26%. Health care institutions were 15%, and non-contracted third-party payors were 6%.
This model can scale if volumes rise and software lowers review costs. It can also break if reimbursement rules change, claims are challenged, or FDA issues slow product work. That is why Medicare LCDs, Zio AT billing, and FDA clearances matter so much.
Zio is the center
Zio Monitor
Zio Monitor is the core extended Holter service. The patch records ECG data for up to 14 days, then iRhythm turns that data into a report for the doctor.
Zio AT
Zio AT adds mobile cardiac telemetry for higher-acuity monitoring. It is also the product tied to the DOJ reimbursement investigation, so it carries both growth value and legal risk.
Traditional Holter services
Traditional Holter monitoring gives iRhythm a place in older monitoring workflows. It is less exciting than long-term patch monitoring, but it helps keep the service suite complete.
Next-generation Zio MCT
The next-generation mobile cardiac telemetry product is planned for launch in the first half of 2027. It could help iRhythm compete for more high-acuity monitoring volume.
Next-generation AI algorithm
The company submitted a 510(k) for this algorithm in 2025. Management says it could reduce clinical technician review time by as much as half over time across Zio Monitor, Zio AT, and future Zio MCT.
Japan commercial launch
iRhythm launched commercially in Japan in 2025. Early reimbursement was set at the standard Holter monitoring level, so the larger opportunity depends on proving value and winning better payment.
Revenue by payer
iRhythm reports one operating segment. This mix is by payer type for the three months ended March 31, 2026, so it shows who paid, not separate business lines.
What could go wrong
DOJ review of Zio AT claims
High impact · Medium oddsThe DOJ Civil Investigative Demand focuses on Zio AT reimbursement. The exact scope and possible financial exposure are still unknown. A settlement, billing change, or wider probe could hurt cash flow and trust.
Medicare coverage and payment changes
High impact · Medium oddsCMS was 26% of Q1 2026 revenue, so Medicare rules matter. Proposed Medicare LCDs could change when ambulatory cardiac monitoring is covered and how claims are handled. Unfavorable final language could slow orders or lower payment.
FDA warning-letter cleanup
High impact · Medium oddsiRhythm is still working through issues tied to the May 2023 FDA warning letter and later Form 483 observations. Two late-2024 Zio AT clearances helped, but the warning-letter overhang is not fully closed. Slow remediation could delay products and keep the risk premium high.
AI clearance slips or savings disappoint
Medium impact · Medium oddsThe next-generation AI algorithm is a key margin catalyst. Management says it could cut technician review time by as much as half over time, but FDA clearance and real-world rollout still have to happen. If savings take longer, margin hopes may be too high.
Cybersecurity and patient data
Medium impact · Medium oddsiRhythm handles sensitive patient health data. A June 2026 Form 8-K disclosed unauthorized access to third-party-hosted business applications and data exfiltration. Even if financial impact is limited, patient data events can bring legal cost and customer concern.
High expectations in the stock
Medium impact · High oddsFinn's valuation score is low, which means the market price already gives iRhythm credit for a better future. If revenue growth slows, margins stall, or legal news worsens, the stock could react sharply. Good companies can still be poor stocks when the price is too demanding.
In one breath
What does iRhythm Technologies do?
iRhythm provides remote cardiac monitoring services. Its Zio patch records heart rhythm data, and its cloud platform helps turn that data into reports doctors use.
How does iRhythm make money?
Most money comes from reimbursement by commercial insurers and Medicare after a doctor orders a Zio service. A smaller share comes from health care institutions.
Why is Zio AT important?
Zio AT is a mobile cardiac telemetry service that can serve higher-acuity monitoring needs. It is also central to the DOJ reimbursement investigation, which makes it important to both the bull and bear cases.
What is the next big catalyst for IRTC?
FDA clearance of the next-generation AI algorithm is a major one. If cleared and rolled out well, it could lower clinical review time and support better gross margins.